Loading clinical trials...
Loading clinical trials...
A Single-center, Randomized, Double-blind, Two-cycle, Two-way Crossover Phase Ib Study to Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis
Conditions
Interventions
TQC3564 tablets
Placebo tablets
+2 more
Locations
1
China
Xiangya Hospital Central South University
Changsha, Hunan, China
Start Date
September 14, 2022
Primary Completion Date
May 9, 2023
Completion Date
December 14, 2023
Last Updated
November 26, 2024
NCT06732414
NCT05494346
NCT06061848
NCT06603935
NCT06151938
NCT05186025
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions